As the complexity of active pharmaceutical ingredients goes up, and includes small molecule options and biologics, the number of parenteral drugs has gone up as well. The number of new molecular products which have received the approval of regulatory bodies such as the FDA has gone up and has aided the growth of the industry for the foreseeable future. Major players in the parenteral drugs market are focusing their efforts on expanding their operations in terms of new countries to leverage opportunities in untapped markets, and also setting up new facilities for target markets. In a bid to secure a larger share of the market, manufacturers are also investing in the consolidation of extant production facilities.
Asia Pacific Being Targeted by Manufacturers
Major pharmaceutical companies from around the world are seeking the acquisition of smaller regional competitors, particularly those in the emerging markets of the Asia Pacific region, with the aim of maintaining sustainable rates of growth in terms of parenteral drugs. Further hospital pharmacies are gaining importance as primary channels of distribution owing to higher rates of hospitalization and the rising availability of requisitely skilled man power resources. Similar growth is also being projected for revenue being made by retail pharmacies.
Automation and Single Use Trends Support Rise
Single use strategies have been gaining traction in terms of proteins, antibodies, vaccines, cell therapy, and gene therapy processes. In addition, the FDA has been increasingly pushing for a higher rate of adoption of automation tech in the manufacturing of pharmaceuticals. On the other hand, adequately equipped automation technologies have not been developed for advanced products such as biologics, which is a key issue as manufacturers continue to raise the quality of their offerings.
You can Request an Example Copy from here - https://www.factmr.com/connectus/sample?flag=S&rep_id=3189
Single use technologies allows easier maintenance of quality standards for biologics parenteral drugs, even as the overall market value is projected to reach USD 802 billion by the end of the forecast period in 2029.
In a recent business intelligence study, Fact.MR presents the nitty-gritty of the global parenteral drugs market considering 2014-2018 as the historic year and 2019–2029 as the stipulated timeframe.
The business report highlights the drivers, restraints, opportunities and trends affecting parenteral drugs market growth.
Further, all the market shares associated with the market as well as the segments are expressed in terms of value and volume.
Parenteral drugs are types of medications that require non-oral types of administration, mostly through the direct injection of drugs into the body of the patient either in intravenous, intramuscular, and subcutaneous methods.
As the complexity of active pharmaceutical ingredients goes up, and includes small molecule options and biologics, the number of parenteral drugs has gone up as well.
The number of new molecular products which have received the approval of regulatory bodies such as the FDA has gone up and has aided the growth of the industry for the foreseeable future.Asia Pacific Being Targeted by ManufacturersMajor pharmaceutical companies from around the world are seeking the acquisition of smaller regional competitors, particularly those in the emerging markets of the Asia Pacific region, with the aim of maintaining sustainable rates of growth in terms of parenteral drugs.Further hospital pharmacies are gaining importance as primary channels of distribution owing to higher rates of hospitalization and the rising availability of requisitely skilled man power resources.
